Dicloxacillin

CHEMBL893 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

470.3 g/mol

LogP

2.9

Phase

4

A penicillinase-resistant isoxazolyl penicillin that resists staphylococcal beta-lactamase and is used orally to treat mild-to-moderate skin and soft tissue infections caused by staphylococci and streptococci. It must be taken on an empty stomach due to food-reduced absorption.

Moleküler Ağırlık

470,3000 g/mol

LogP

2,90

TPSA

138,00 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Atopic Dermatitis

Etki Mekanizması

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O

InChI

InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1

Molecular Formula

C19H17Cl2N3O5S

HBD / HBA

2 / 7

Döndürülebilir Bağlar

4

Ağır Atomlar

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A penicillinase-resistant isoxazolyl penicillin that resists staphylococcal beta-lactamase and is used orally to treat mild-to-moderate skin and soft tissue infections caused by staphylococci and streptococci. It must be taken on an empty stomach due to food-reduced absorption.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Dicloxacillin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL893. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 18381. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Dicloxacillin PillFYI'da

Yapı

Hızlı Veriler

Formül: C19H17Cl2N3O5S

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.